This program has published several clinical performance guidelines [ 4], based in part upon evidence of improved outcomes and in part upon expert judgment, that address aspects of end-stage renal disease (ESRD) patient care related to nutrition, bone disease management, anemia management, adequacy of dialysis, and vascular access placement.
However, whether attainment of accepted clinical performance targets for nutrition, bone disease management, anemia management, dialysis adequacy, and vascular access placement by hemodialysis patients have led to fewer hospitalizations, fewer hospital days, or decreased hospitalization costs, in addition to better patient survival, has been less well-studied [ 23, 24].
This review is aimed to underline the new molecular targets in bone metastases management other than bisphosphonates.
The traditional clinical methods of bone defect management, such as autografts and allografts of cancellous bone, can be limited by the large size of bone defects, poor viability of host environment and unpredictable graft resorption (Burg et al. 2000).
Four patients were taking i.v. BPT as part of their bone cancer management and 16 were taking oral BPT for osteoporosis.
This article provides a review of contemporary methods of bone loss management with a focus on highly porous metals and an emphasis on the authors' preferred method for managing the severe bone loss in revision TKA.
Improvements in bone healing management will probably also come from a combination of ultrasound with a 'biologic' components, e.g. growth factors, scaffolds, gene therapies, or drug delivery vehicles, the effects of which being potentiated by the ultrasound.
The main limitations of current scaffolds include the lack of sufficient vascularisation, insufficient mechanical strength as well as issues relating to the osseointegration of the bioresorbable scaffold and bone infection management.
The study investigated whether the type of bone disease management (aggressive versus conventional) had an impact on clinical outcomes, namely bone health measures (e.g., biointact parathyroid hormone [BiPTH], serum corrected calcium [cCa] level, serum phosphorus [phos] level, and corrected calcium-phosphorus product [cCaPO4]).
These data highligh the central role of RANK/RANKL/OPG pathway as therapeutic target in bone metastasis management.
